A Phase II, Single-Arm Open-Label Study Of The Combination Of Atezolizumab And Bevacizumab In Rare Solid Tumors
Phase of Trial: Phase II
Latest Information Update: 26 Oct 2018
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Mesothelioma; Pharyngeal neoplasms; Soft tissue sarcoma; Solid tumours
- Focus Therapeutic Use
- 17 Oct 2018 Planned End Date changed from 1 Mar 2022 to 1 Mar 2021.
- 15 Mar 2018 Planned End Date changed from 1 Mar 2021 to 1 Mar 2022.
- 15 Mar 2018 Status changed from active, no longer recruiting to recruiting.